Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-214 long-term extension in schizophrenia
NCT01626872Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Sep 2012
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of cariprazine in schizophrenia (4 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Adverse Events at 60 weeks. Started Sep 2012; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01626872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01626872.